Current Diabetes Reports最新文献_第2页

Climate Change and Diabetes Outcomes: Evidence from Climate-Vulnerable Regions. 气候变化与糖尿病结局：来自气候脆弱地区的证据。

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-06-16 DOI: 10.1007/s11892-026-01634-5

Lakshmi Natarajan, Anjana Ranjit Mohan, Hamad Ali, Gary Adamkiewicz, Pradeepa Rajendra, Fahd Al-Mulla, Viswanathan Mohan, Barrak Alahmad

{"title":"Climate Change and Diabetes Outcomes: Evidence from Climate-Vulnerable Regions.","authors":"Lakshmi Natarajan, Anjana Ranjit Mohan, Hamad Ali, Gary Adamkiewicz, Pradeepa Rajendra, Fahd Al-Mulla, Viswanathan Mohan, Barrak Alahmad","doi":"10.1007/s11892-026-01634-5","DOIUrl":"10.1007/s11892-026-01634-5","url":null,"abstract":"Purpose of review: Climate change is progressively recognized as an emerging determinant of metabolic health outcomes, particularly in relation to diabetes mellitus. This review summarizes mechanistic and epidemiological evidence linking climate-related exposures to diabetes outcomes: namely, 1) heat stress, 2) air pollution, and 3) extreme weather-related disruption of diabetes care.Recent findings: Warming temperatures, worsening air quality, and more frequent extreme weather events are intensifying exposures that disproportionately affect populations with pre-existing chronic diseases; patients with diabetes may be at the center of climate-related vulnerability. While the greatest burden of diabetes is shouldered by countries in the Global South, these same regions are also at the front lines of climate change, facing extreme environmental conditions. Together, diabetes and climate change can converge to create compounding pressures on already strained public health systems in the world's most climate-vulnerable regions. Using global case studies from climate-vulnerable settings, we show the pathways through which diabetes outcomes and climate change can be connected highlighting the need for climate-informed diabetes prevention and management.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of once-weekly basal insulin analogs versus daily basal insulin analogs in adults with type 2 diabetes: a systematic review and meta-analysis. 成人2型糖尿病患者每周一次基础胰岛素类似物与每日基础胰岛素类似物的疗效和安全性：一项系统综述和荟萃分析

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-06-12 DOI: 10.1007/s11892-026-01628-3

Dimitrios Raptis, Sotirios Chiotis, Theodoros Papamichalis, Eleni Bekiari, Apostolos Tsapas, Thomas Karagiannis

{"title":"Efficacy and safety of once-weekly basal insulin analogs versus daily basal insulin analogs in adults with type 2 diabetes: a systematic review and meta-analysis.","authors":"Dimitrios Raptis, Sotirios Chiotis, Theodoros Papamichalis, Eleni Bekiari, Apostolos Tsapas, Thomas Karagiannis","doi":"10.1007/s11892-026-01628-3","DOIUrl":"10.1007/s11892-026-01628-3","url":null,"abstract":"Purpose of review: Recently developed once-weekly basal insulin analogs, including insulin icodec and insulin efsitora alpha (efsitora), aim to improve treatment adherence and patient convenience compared with daily basal insulin. This systematic review and meta-analysis evaluated the efficacy and safety of once-weekly basal insulin analogs compared with daily basal insulin analogs in adults with type 2 diabetes mellitus (T2DM) and included 14 randomized controlled trials (RCTs), comprising 8,487 subjects.Recent findings: Evidence supports that once-weekly basal insulin analogs achieve comparable glycemic control to daily basal insulin analogs in adults with T2DM, offering greater reductions in HbA1c and improvements in time in range, with a safety profile similar to that of daily insulin regimens. In our analysis, once-weekly basal insulin resulted in a greater reduction in HbA1c compared with daily basal insulin (mean difference [MD] -0.09%, 95% CI -0.15 to -0.03), greater improvements in time in range (TIR) (MD 1.86%, 95% CI 0.73 to 2.98) and higher odds of attaining an HbA1c < 7.0% (OR 1.32, 95% CI 1.07 to 1.63, I2 64.9%). Rates of level 2 or 3 hypoglycemia did not differ significantly. Once-weekly basal insulin provides glycemic control comparable to daily basal insulin, with modest improvements in glycemic outcomes and similar hypoglycemia risk. Its primary advantage lies in treatment simplification and reduced injection burden, supporting its role as a convenient alternative to daily basal insulin in adults with T2DM.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13260229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148223829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of Glucagon-Like Peptide-1 Receptor Agonists in Women with Type 2 Diabetes Before Pregnancy: Addressing the Dilemma in A Real-World Setting. 妊娠前2型糖尿病妇女使用胰高血糖素样肽-1受体激动剂：解决现实世界环境中的困境

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-06-09 DOI: 10.1007/s11892-026-01632-7

Aria Amiri, Sofie Hædersdal, Peter Damm, Elisabeth R Mathiesen, Lene Ringholm

{"title":"Use of Glucagon-Like Peptide-1 Receptor Agonists in Women with Type 2 Diabetes Before Pregnancy: Addressing the Dilemma in A Real-World Setting.","authors":"Aria Amiri, Sofie Hædersdal, Peter Damm, Elisabeth R Mathiesen, Lene Ringholm","doi":"10.1007/s11892-026-01632-7","DOIUrl":"10.1007/s11892-026-01632-7","url":null,"abstract":"Purpose of review: To address the clinical dilemma of how best to counsel women with type 2 diabetes (T2D) using glucagon-like peptide-1 receptor agonists (GLP-1RA) regarding pregnancy.Recent findings: Animal studies raise concern for fetal loss, malformations and adverse fetal growth after GLP-1RA exposure. Nonetheless, three cohort studies and one prospective study including 2,994 women with T2D exposed to GLP-1RA in early pregnancy indicate no increased risk of malformations compared with unexposed pregnancies, and observational data in 168 GLP-1RA exposed pregnancies are reassuring regarding miscarriage and fetal growth. Women with T2D are advised to use contraception and to discontinue GLP-1RAs two months before planned pregnancy. Despite concerns in animal studies, GLP-1RA exposure in early T2D pregnancy has not been associated with increased risk of malformations. If a woman with T2D inadvertently becomes pregnant while using GLP-1RA, the existing human evidence does not support a recommendation of terminating pregnancy.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148204489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can Behavioral Interventions Promote Health Equity in Pediatric Type 1 Diabetes? A Narrative Review of Promising Treatments. 行为干预能促进儿童1型糖尿病的健康公平吗？前景治疗的叙述性回顾。

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-05-30 DOI: 10.1007/s11892-026-01629-2

Paul T Enlow, Jaquelin Flores Garcia, Julia Price, Kristen A Torres, David V Wagner

{"title":"Can Behavioral Interventions Promote Health Equity in Pediatric Type 1 Diabetes? A Narrative Review of Promising Treatments.","authors":"Paul T Enlow, Jaquelin Flores Garcia, Julia Price, Kristen A Torres, David V Wagner","doi":"10.1007/s11892-026-01629-2","DOIUrl":"10.1007/s11892-026-01629-2","url":null,"abstract":"Purpose of review: Synthesize data on whether existing behavioral interventions can improve health equity among youth with type 1 diabetes.Recent findings: While existing behavioral interventions demonstrated efficacy in improving health and/or psychosocial outcomes, evidence that these same interventions may improve health equity were lacking. Most interventions were evaluated using predominantly White and affluent samples and some studies did not report on racial, ethnic, or sociodemographic characteristics of their sample. Only a few interventions have been adapted for youth from minoritized backgrounds. Recent multisystemic and technology/mHealth interventions recruited samples that were sociodemographically representative of youth experiencing disparities, suggesting that these interventions could improve health and/or psychosocial outcomes for these sociodemographic groups. However, no studies conducted subgroup analyses to examine whether the effect of the intervention might vary as a function of sociodemographic characteristics. The prevalence and persistence of disparities in psychosocial and glycemic outcomes among youth with T1D underscore the urgent need for effective, evidence-based behavioral interventions for populations in most need of this care. There is a critical need for research that prioritizes recruitment of samples that represent youth most impacted by health disparities. Additionally, existing interventions can be adapted for youth from minoritized backgrounds. Future research would benefit from leveraging existing intervention development/adaptation frameworks and engaging community partners through the research process.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13221396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148052934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Implementation Strategies to Address Cardiometabolic Disparities in Black Men: Lessons from Existing Research and Future Directions. 更正：解决黑人男性心脏代谢差异的实施策略：来自现有研究和未来方向的教训。

IF 6.4 2区医学

Current Diabetes Reports Pub Date : 2026-05-22 DOI: 10.1007/s11892-026-01630-9

Jaclynn Hawkins

引用次数: 0

Type 2 Diabetes and the Lung - Cause and Consequence. 2型糖尿病与肺部——原因和后果。

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-05-07 DOI: 10.1007/s11892-026-01625-6

Dinah Foer, Tianshi David Wu, Juan C Celedón, M Furkan Burak, Vanita R Aroda

{"title":"Type 2 Diabetes and the Lung - Cause and Consequence.","authors":"Dinah Foer, Tianshi David Wu, Juan C Celedón, M Furkan Burak, Vanita R Aroda","doi":"10.1007/s11892-026-01625-6","DOIUrl":"10.1007/s11892-026-01625-6","url":null,"abstract":"Purpose of review: The purpose of this review is to synthesize literature investigating the relationship between type 2 diabetes (T2D) and obstructive airway diseases and to identify implications for clinical care.Recent findings: Type 2 diabetes is a common and challenging comorbidity in patients with asthma and chronic obstructive pulmonary disease (COPD). Basic, translational and clinical studies support a bidirectional association between T2D and the lung. In animal models and human studies, insulin resistance and hyperglycemia are associated with pulmonary inflammation, respiratory exacerbation risk and disease severity. Corticosteroids are a mainstay for respiratory disease control and exacerbation treatment but promote ongoing metabolic dysregulation. Randomized, placebo-controlled trials of glucose-lowering medications for asthma are actively ongoing. Additional studies addressing clinical pathways to co-manage respiratory and metabolic risk are needed. Patients with comorbid T2D and asthma or COPD are at risk for worse outcomes. There are opportunities to improve cross-disciplinary care, potentially reducing risk and multimorbidity associated with both conditions.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes. 2型糖尿病肥胖的药物治疗

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-04-13 DOI: 10.1007/s11892-026-01626-5

Caterina Conte, Anastassia Amaro

{"title":"Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes.","authors":"Caterina Conte, Anastassia Amaro","doi":"10.1007/s11892-026-01626-5","DOIUrl":"10.1007/s11892-026-01626-5","url":null,"abstract":"Purpose of review: To examine the role of pharmacologic obesity treatment in people with type 2 diabetes (T2D), with a focus on efficacy, safety, and clinical positioning in the context of T2D-specific metabolic and therapeutic challenges.Recent findings: Contemporary incretin receptor agonists enable clinically meaningful weight loss in people with T2D while improving glycemic control and cardio-renal, hepatic, and functional outcomes, including improvements in physical performance and symptoms in heart failure with preserved ejection fraction (HFpEF). However, weight loss is consistently attenuated compared with obesity without diabetes, reflecting reduced metabolic flexibility (impaired ability to appropriately adjust fuel utilization), background therapies, and social determinants of health rather than treatment failure. Obesity pharmacotherapy should be considered a disease-modifying component of T2D care. Treatment success should be defined by improvements in adiposity-related complications, organ protection, and patient-centered outcomes, not by fixed weight-loss thresholds. A complication-focused, individualized approach is essential to optimize long-term benefit in T2D.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147671049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dysregulation of the Gut-Adipose Tissue-Liver Axis: a Possible Mechanism Behind the Relationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes. 肠-脂肪组织-肝轴的失调：代谢功能障碍相关的脂肪变性肝病与2型糖尿病之间关系的可能机制

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-04-11 DOI: 10.1007/s11892-026-01623-8

Susanna Longo, Tommaso Giovanni Rinaldi, Jose Manuel Fernández-Real, Massimo Federici

{"title":"Dysregulation of the Gut-Adipose Tissue-Liver Axis: a Possible Mechanism Behind the Relationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes.","authors":"Susanna Longo, Tommaso Giovanni Rinaldi, Jose Manuel Fernández-Real, Massimo Federici","doi":"10.1007/s11892-026-01623-8","DOIUrl":"10.1007/s11892-026-01623-8","url":null,"abstract":"Purpose of review: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a hepatic manifestation of metabolic syndrome, frequently occurring alongside type 2 diabetes (T2D), and it can present in varied phenotypes. This review provides a critical analysis of gut-adipose tissue-liver axis (GALA) dysregulation in MASLD pathogenesis, contextualizing the discussion within both established and emerging paradigms. The review elucidates how GALA dysregulation shapes the interplay between MASLD and T2D, emphasizing inter-organ crosstalk among the gut, liver, and adipose tissue, and highlighting the role of microbial metabolites, notably bile acids. The review further summarizes recent advances in stratifying MASLD into distinct clusters, examining intricate associations with cardiometabolic comorbidities, and critically evaluates novel therapeutic approaches targeting GALA modulation.Recent findings: MASLD can show heterogeneous phenotypes. It significantly increases the risk of developing new-onset T2D, and both conditions often coexist due to their shared pathophysiological basis in insulin resistance. The gut microbiota influences immune function and modulates host metabolism by regulating glucose tolerance and insulin sensitivity through a specific crosstalk between the gut, liver, and adipose tissue. The dysregulation of the GALA may be a mechanism underlying the interplay between MASLD and T2D, influencing IR and metabolic syndrome. A thorough investigation of GALA's role in the physiopathogenesis of MASLD and T2D highlights its potential to distinguish specific MASLD clusters and to identify personalized therapeutic strategies.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13070062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147662529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Glucagon-Like Peptide-1 and Dual Incretin Agonists in Type 2 Diabetes with Peripheral Artery Disease: A Systematic Review and Meta-Analysis of Vascular, Cardiovascular, Metabolic, and Mortality Outcomes. 更正：胰高血糖素样肽-1和双重肠促胰岛素激动剂治疗伴有外周动脉疾病的2型糖尿病：血管、心血管、代谢和死亡率结局的系统回顾和荟萃分析。

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-04-10 DOI: 10.1007/s11892-026-01622-9

Larissa Araújo de Lucena, Deivyd V S Cavalcante, Marcela V Montenegro, Larissa C Hespanhol, William S de Oliveira, Juliana Q Muniz, Sruti Prathivadhi-Bhayankaram, Edgardo Kaplinsky, Alejandro Barbagelata, Juliana Giorgi

引用次数: 0

Lipolysis in Health and Disease: Pathways, Regulation, and Metabolic Consequences. 健康和疾病中的脂肪分解：途径、调节和代谢后果。

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-04-10 DOI: 10.1007/s11892-026-01624-7

Courtney L Bordelon, Jacqueline M Stephens

{"title":"Lipolysis in Health and Disease: Pathways, Regulation, and Metabolic Consequences.","authors":"Courtney L Bordelon, Jacqueline M Stephens","doi":"10.1007/s11892-026-01624-7","DOIUrl":"10.1007/s11892-026-01624-7","url":null,"abstract":"PURPOSE OF REVIEW: Lipolysis regulates lipid distribution, energy availability, and metabolic homeostasis in organisms that store triacylglycerols. In multicellular organisms, adipose tissue evolved as a specialized organ that centralizes lipid storage and release, buffers nutrient fluctuations, and protects non-adipose tissues from lipid overload. Dysregulated adipocyte lipolysis occurs across diverse metabolic conditions, including obesity, diabetes, lipodystrophy, and inflammatory states. This review synthesizes evidence that defective suppression of basal lipolysis and impaired responsiveness to physiological stimuli disrupt lipid partitioning, promote insulin resistance, and drive ectopic lipid accumulation. RECENT FINDINGS: Research shows that metabolic dysfunction arises in both obese and non-obese settings and correlates more closely with impaired control of fatty acid flux than with adiposity itself. Higher expression of lipolytic receptors, including those targeted by weight-loss medications, together with genes that regulate lipolysis through insulin signaling, is associated with greater weight loss and improved systemic metabolic health. In this review, we highlight canonical and noncanonical mechanisms governing lipolytic regulation and contrast pathological lipolysis with the tightly controlled lipolysis observed during weight loss. Together, these findings reframe lipolysis as a central determinant of metabolic health and a therapeutic target when precisely regulated. ","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13068693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147644453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0